Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SCHOOL SPECIALTY INCSCOO · Entity 16699 | Director | June 18, 2019 | June 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SCHOOL SPECIALTY INC
Report date June 18, 2019 · Filed June 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,870 |
Reported balance
After 2019-06-18 transaction · row 1
1 source rowRow 1 · 2019-06-18 · Exercise / conversion · Acquired 3,870 · Balance 3,870 F1: RSUs vested on June 18, 2019 and were settled in shares of School Specialty, Inc. common stock on a one-for-one basis. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-18 · Exercise / conversion · Disposed 3,870 · Balance 0 F1: RSUs vested on June 18, 2019 and were settled in shares of School Specialty, Inc. common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs vested on June 18, 2019 and were settled in shares of School Specialty, Inc. common stock on a one-for-one basis.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptimizeRx Corp
Report date June 05, 2024 · Filed June 11, 2024
Section 16 reporting ended · disclosed 2024-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,926 |
Reported balance
After 2024-06-05 transaction · row 1
1 source rowRow 1 · 2024-06-05 · Exercise / conversion · Acquired 10,061 · Balance 80,926 F1: Restricted stock units convert into common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-05 · Exercise / conversion · Disposed 10,061 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On June 7, 2023 the reporting person was granted 10,061 restricted stock units which vested in full on June 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On June 7, 2023 the reporting person was granted 10,061 restricted stock units which vested in full on June 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2024 Filed Jun 11, 2024 21:48 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 10,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027712 · wk-form4_1718142490.xml · derivative · entry 2 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 7, 2023 the reporting person was granted 10,061 restricted stock units which vested in full on June 5, 2024. F2 · derivative.expiration_date: On June 7, 2023 the reporting person was granted 10,061 restricted stock units which vested in full on June 5, 2024. Read SEC document |
| June 05, 2024 Filed Jun 11, 2024 21:48 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 10,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027712 · wk-form4_1718142490.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 07, 2023 Filed Aug 18, 2023 14:03 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 10,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029934 · wk-form4_1692367398.xml · derivative · entry 3 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,061 Underlying: Common Stock · 10,061 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Aug 18, 2023 14:03 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029934 · wk-form4_1692367398.xml · derivative · entry 2 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 7, 2022 the reporting person was granted 4,637 restricted stock units which vested in full on June 7, 2023. F2 · derivative.expiration_date: On June 7, 2022 the reporting person was granted 4,637 restricted stock units which vested in full on June 7, 2023. Read SEC document |
| June 07, 2023 Filed Aug 18, 2023 14:03 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029934 · wk-form4_1692367398.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 16:22 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-010322 · wf-form4_168053893397096.xml · derivative · entry 2 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On March 30, 2022 the reporting person was granted 657 restricted stock units which vested in full on March 30, 2023. F2 · derivative.expiration_date: On March 30, 2022 the reporting person was granted 657 restricted stock units which vested in full on March 30, 2023. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 16:22 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-010322 · wf-form4_168053893397096.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:10 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000220 · wf-form4_167286656067394.xml · derivative · entry 2 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 30, 2021 the reporting person was granted 334 restricted stock units which vested in full on December 30, 2022. F2 · derivative.expiration_date: On December 30, 2021 the reporting person was granted 334 restricted stock units which vested in full on December 30, 2022. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:10 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000220 · wf-form4_167286656067394.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:44 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025810 · wf-form4_166457066314869.xml · derivative · entry 2 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On September 29, 2021 the reporting person was granted 334 restricted stock units which vested in full on September 29, 2022. F2 · derivative.expiration_date: On September 29, 2021 the reporting person was granted 334 restricted stock units which vested in full on September 29, 2022. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:44 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025810 · wf-form4_166457066314869.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-032529 · ownership.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637 Underlying: Common Stock · 4,637 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F2 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:47 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-017500 · ownership.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest on March 30, 2023. F2 · derivative.expiration_date: The restricted stock units vest on March 30, 2023. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-000274 · ownership.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 Underlying: Common Stock · 409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-051140 · ownership.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334 Underlying: Common Stock · 334 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on September 29, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 20:47 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 407 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-035076 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,828 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:33 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 539 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-019875 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,421 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 802 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-000455 · ownership.xml · nonDerivative · entry 2 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,882 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 1,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-000455 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,080 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:33 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 1,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-016581 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,897 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 12:46 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008139 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,960 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 21:30 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-000381 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,176 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:10 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 5,000 | $9.80 | $49,000.00 |
DisclosureSEC source: 0001213900-19-023179 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,092 Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:15 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-019541 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,092 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 16:12 UTC | SCHOOL SPECIALTY INC SCOO · Entity 16699 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 3,870 | $0.00 | $0.00 |
DisclosureSEC source: 0000892712-19-000259 · edgar.xml · derivative · entry 2 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,870 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: RSUs vested on June 18, 2019 and were settled in shares of School Specialty, Inc. common stock on a one-for-one basis. F1 · derivative.exercise_date: RSUs vested on June 18, 2019 and were settled in shares of School Specialty, Inc. common stock on a one-for-one basis. F1 · derivative.expiration_date: RSUs vested on June 18, 2019 and were settled in shares of School Specialty, Inc. common stock on a one-for-one basis. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 16:12 UTC | SCHOOL SPECIALTY INC SCOO · Entity 16699 | Exercise / conversionCommon Stock | 3,870 | $0.00 | $0.00 |
DisclosureSEC source: 0000892712-19-000259 · edgar.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: RSUs vested on June 18, 2019 and were settled in shares of School Specialty, Inc. common stock on a one-for-one basis. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 16:37 UTC | SCHOOL SPECIALTY INC SCOO · Entity 16699 | GrantRestricted Stock Units (RSUs) · Derivative | 3,870 | $0.00 | $0.00 |
DisclosureSEC source: 0000892712-19-000244 · edgar.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 Underlying: Common Stock · 3,870 shares Expires not disclosed F1 · derivative.exercise_price: These RSUs will become 100% vested on 6/6/2020. When they vest, they will be settled in shares of common stock on a 1-for-1 basis. F1 · derivative.exercise_date: These RSUs will become 100% vested on 6/6/2020. When they vest, they will be settled in shares of common stock on a 1-for-1 basis. F1 · derivative.expiration_date: These RSUs will become 100% vested on 6/6/2020. When they vest, they will be settled in shares of common stock on a 1-for-1 basis. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 20:18 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005240 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,008 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 14:16 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 3,000 | $14.30 | $42,900.00 |
DisclosureSEC source: 0001213900-18-016264 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,924 Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 21:18 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-013765 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,924 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 18:42 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-008677 · ownership.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,840 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 16:43 UTC | SCHOOL SPECIALTY INC SCOO · Entity 16699 | GrantRestricted Stock Units (RSUs) · Derivative | 3,870 | $0.00 | $0.00 |
DisclosureSEC source: 0000892712-18-000287 · edgar.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 Underlying: Common Stock · 3,870 shares Expires not disclosed F1 · derivative.exercise_price: These RSUs will become 100% vested on 6/18/19. When they vest, they will be settled in shares of common stock on a 1-for-1 basis. F1 · derivative.exercise_date: These RSUs will become 100% vested on 6/18/19. When they vest, they will be settled in shares of common stock on a 1-for-1 basis. F1 · derivative.expiration_date: These RSUs will become 100% vested on 6/18/19. When they vest, they will be settled in shares of common stock on a 1-for-1 basis. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:32 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-000486 · f4011018halas_optimizerx.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,269 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 19:07 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-010179 · f4092917halas_optimizerx.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,019 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 20:46 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007051 · f4063017halas_optimizerx.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,769 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:03 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-003336 · f4033117halas_optimizerx.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,519 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 21, 2017 Filed Mar 21, 2017 20:55 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 16,990 | $0.77 | $13,082.30 |
DisclosureSEC source: 0001213900-17-002655 · f4032017halas_optimizerx.xml · nonDerivative · entry 2 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,269 Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 20:55 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 5,000 | $0.77 | $3,850.00 |
DisclosureSEC source: 0001213900-17-002655 · f4032017halas_optimizerx.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,279 Read SEC document |
| March 09, 2017 Filed Mar 15, 2017 17:23 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 8,010 | $0.74 | $5,927.40 |
DisclosureSEC source: 0001213900-17-002336 · f4030817halas_optimizerx.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,279 Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:11 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-000068 · f4123116halas_optimizerx.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,269 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.